Encompass Health (EHC)
Health Care · inpatient rehabilitation services · NYSE
Encompass Health is the nation’s leading provider of inpatient rehabilitation services, focused on improving patient outcomes through specialized, evidence-based care for complex neurological and physical recovery.
What Encompass Health does
Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States, providing specialized rehabilitative treatment for patients recovering from major injuries or illnesses, such as strokes and hip fractures. The company utilizes interdisciplinary clinical teams to deliver intensive, facility-based therapy aimed at restoring patient functional ability and independence. Its operations are heavily integrated with the Medicare program and acute-care hospital referral networks across 39 states and Puerto Rico.
Themes: post-acute care, aging demographics, stroke recovery, value-based care, hospital infrastructure
Fundamentals
- Price$121.67 as of 2026-10-20 close
- Market cap$12.0B as of 2026-07-28 (share count; price 2026-10-20)
- 1-year return-2.8% 2025-10-20 close $125.20 → 2026-10-20 close $121.67
- P/E19.82 as of 2026-10-20
- Net margin+9.5% FY2025, SEC XBRL
- ROE+23.2% FY2025, SEC XBRL
- ROICn/a No figure: its filing reports debt only together with finance leases, and ROIC's debt excludes leases.
- Debt / equity1.01 borrowings incl. finance leases / equity — 10-Q/10-K balance sheet 2026-06-30
- Revenue growth (YoY)+10.5% FY2025, SEC XBRL
- Revenue CAGR (3y)+10.9% SEC XBRL
- Beta0.42 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.7%; 3-year non-decreasing per-share dividend streak (SEC XBRL).
How EHC compares in its sector
- price-to-earnings ratiomiddle range 181 covered Health Care peers, as of 2026-10-20
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 63 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
EHC is not currently in any published Top 10 list. Its scores are below.
Top 10 score
56.0 #387 of 1,265 scored · #59 of 146 in Health Care
Profitability 66th (return on equity 23.2%, operating margin 12.4%) and growth 63rd (3-year revenue CAGR 10.9%, revenue growth year over year 10.5%); weakest is financial health (36th, debt to equity 1, free cash flow margin 7.4%).
Scores as of 20 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, EHC's dividend was covered by reported results (earnings payout 13%, free-cash-flow payout 16%). This describes past coverage, not a forecast.
- Earnings payout13% dividends / net income
- Free-cash-flow payout16% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
Quarterly results
| Quarter | Revenue | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $1.6B | $154M | $1.54 | $283M† | $220M† |
| Q1 FY2026 2026-03-31 | $1.6B | $195M | $1.93 | $313M | $162M |
| Q4 FY2025 2025-12-31 | $1.5B† | $146M† | $1.43† | $346M† | $229M† |
| Q3 FY2025 2025-09-30 | $1.5B | $127M | $1.24 | $271M† | $187M† |
| Q2 FY2025 2025-06-30 | $1.5B | $142M | $1.39 | $270M† | $157M† |
| Q1 FY2025 2025-03-31 | $1.5B | $152M | $1.48 | $289M | $163M |
| Q4 FY2024 2024-12-31 | $1.4B† | $121M† | $1.18† | $279M† | $199M† |
| Q3 FY2024 2024-09-30 | $1.4B | $108M | $1.06 | $268M† | $148M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$108M
- Total debt$2.6B borrowings incl. finance leases (not tagged separately)
- Net debt$2.5B total debt − cash − short-term investments
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Encompass Health looks technically
Encompass Health (EHC) is trading 11.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 51 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day high about 3 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 11.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $122.42 | $122.42 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $109.29 | $109.29 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 118.39. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 51 trading days ago — a "golden cross", a bullish long-term signal | 51 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 46, neither overbought (above 70) nor oversold (below 30) | 46.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($118.39 to $129.96) — its "stochastic" reading is 28 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 28.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $129.96 | $129.96 |
|---|---|---|
| From the 52-week high | it is 6.4% below its 52-week high (its highest price of the past year) | -6.4% |
| Above the 52-week low | it is 31.2% above its 52-week low (its lowest price of the past year) | +31.1% |
| Below the 52-week high | it is 6.4% below its highest point of the past year | 6.4% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $129.96 (set on 2026-10-15) | $129.96 |
| Given back of the 52-week move | over the past year its closes ranged ($93.83 to $127.87), and it has given back roughly a quarter of its rise from last year’s low — 18% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $105.74 to $106.83. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 18.2% |
| From the all-time high | it is 6.4% below its all-time high | -6.4% |
| Nearest price level | it is trading 0.7% below a resistance level at $122.51 — a price it turned at four times since 2025-05-20, most recently on 2025-07-01. Since 2024-10-21 it has 8 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.7% |
| All-time low | its lowest closing price on record is $0.03978 (set on 2003-04-09) | $0.03978 |
| Above the all-time low | it is 305780.3% above its all-time low | +305,780% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.14 between its high and its low — about 2.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.14 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $118.63 and $127.77 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $118.63 – $123.20 – $127.77 |
| Typical daily range (% of price) | its price moves about 2.6% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.6% |
| Stretch from the 200-day average | it is trading 3.9 daily ranges above its 200-day average price (11.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.43× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.8% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.8% |
|---|---|---|
| Open gap | it gapped 12.5% above the previous close 52 sessions ago and has not traded back through the level it left behind at 110.9 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +12.5% |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.85% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.0 percentage points (the stock lost 0.1% while the market gained 1.0%) | -1.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.5 percentage points (the stock gained 8.2% while the market gained 3.6%) | +4.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 6.0 percentage points (the stock gained 14.5% while the market gained 8.5%) | +6.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 17.4 percentage points (the stock lost 2.8% while the market gained 14.6%) | -17.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 6.8% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $109.12 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | +11.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is under water. That average is $122.44 — a volume-weighted average of daily closes over 54 sessions, not a true tick-by-tick VWAP. | -0.6% |
Price levels it has turned at before
EHC last closed at $121.67 on 2026-10-20. Since 2024-10-21 it has turned at 8 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $122.51 | Resistance | 0.7% above the last close | turned there four times · 2025-05-20 to 2025-07-01 |
| $125.26 | Resistance | 3.0% above the last close | turned there three times · 2025-08-21 to 2026-09-28 |
| $117.59 | Support | 3.4% below the last close | turned there 9 times · 2025-05-23 to 2026-10-02 |
| $127.63 | Resistance | 4.9% above the last close | turned there four times · 2025-09-12 to 2026-08-11 |
| $109.51 | Support | 10.0% below the last close | turned there 7 times · 2025-11-19 to 2026-07-31 |
| $106.36 | Support | 12.6% below the last close | turned there 7 times · 2025-07-16 to 2026-07-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $118.39.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 8 trading days, since 2026-10-09.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading below the 50-day moving average · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.08 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$148.17 range $140.00 – $155.00; median $150.00
Analyst estimates, as of 2026-10-15. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EHC
- Consensus EPS estimate$1.36 next reporting period, as of 2026-10-15
- Estimate change, 30 days-$0.00391 (-0.3%) from $1.36, on 2026-09-10, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High concentration of revenue derived from Medicare and sensitivity to changes in government reimbursement policies.","Risk of audit-related payment denials, recoupments, and increased regulatory compliance costs.","Competitive pressures from Medicare Advantage payors and potential shifts in site-of-care preferences."]
What changed in the latest 10-Q
AI-assisted comparison of EHC's 10-Q filed 2026-08-07 against the prior one filed 2026-05-01.
Management's Discussion & Analysis (MD&A)
- Added:
- As of June 30, 2026, we operated 176 IRFs (newer filing) versus 174 IRFs as of March 31, 2026 (older filing).
- Net operating revenues increased 9.6% and 9.3% for the three and six months ended June 30, 2026, respectively, compared to the same periods of 2025 (newer filing); the older filing reported a 9.0% increase for the three months ended March 31, 2026.
- Began operating a new 50-bed inpatient rehabilitation hospital in Concordville, Pennsylvania in May (newer filing); this project remained in development in the older filing with an expected 2Q26 open date.
- Began operating a new 40-bed inpatient rehabilitation hospital in Loganville, Georgia with joint venture partner Piedmont in June (newer filing); this project remained in development in the older filing with an expected 2Q26 open date and joint venture designation.
- Expanded capacity by adding 54 new beds to existing hospitals during the six months ended June 30, 2026 (newer filing) versus 44 new beds during the three months ended March 31, 2026 (older filing).
- Shareholder distributions description revised from 'during the three months ended March 31, 2026' (older filing) to 'during the six months ended June 30, 2026' (newer filing).
- Removed:
- Removed Concordville, Pennsylvania as a de novo project from the development table in the newer filing; it appeared with 50 new beds and expected open date 2Q26 in the older filing.
- Removed Loganville, Georgia as a de novo project from the development table in the newer filing; it appeared with 40 new beds, expected 2Q26 open date, and expected joint venture designation in the older filing.
- Reworded:
- The newer filing's section on development and expansion efforts covers the 'six months ended June 30, 2026' while the older filing covers the 'three months ended March 31, 2026'.
- The newer filing's 2026 Overview paragraph reports results for 'the three and six months ended June 30, 2026' while the older filing reports for 'the three months ended March 31, 2026' only.
- The IRF count reference date changed from March 31, 2026 to June 30, 2026, with the count changing from 174 to 176.
- The newer filing text ends mid-sentence at 'failure to comply with t' whereas the older filing continues with additional language regarding Medicare program laws and regulations.
- In the newer filing, remaining de novo projects in the table now show only projects with open dates from 3Q26 onward; Concordville and Loganville entries are absent because they have begun operating.
- Notes:
- The newer filing text is truncated at the end of the provided excerpt ('failure to comply with t'), so later portions of the MD&A section are not available for comparison.
- No judgment is made about the materiality or significance of any change; this is a factual comparison only.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 6 sells ($26M) — 4 selling insiders
- Last 180 days · read to 2026-10-160 buys · 9 sells ($29M) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-31. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EHC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for EHC from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding EHC as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 19,286,090
- Reported value $1,949,437,978
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about EHC's institutional holders → See what each manager we track holds →
Short interest (FINRA)
EHC had 3,488,343 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
EHC had 3.54% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.55 days to cover at the same settlement.
- Reported short interest (shares) 3,488,343
- Short interest (% of shares outstanding) 3.54%
- Prior settlement (shares) 3,000,467
- Reported change 16.26%
- Days to cover (reported) 3.55
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Kindred Healthcare
- Select Medical (SEM)
- HCA Healthcare (HCA)
- Community Health Systems (CYH)
- Universal Health Services (UHS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EHC vs…
Encompass Health is found in…
Frequently asked questions
What does Encompass Health (EHC) do?
Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States, providing specialized rehabilitative treatment for patients recovering from major injuries or illnesses, such as strokes and hip fractures. The company utilizes interdisciplinary clinical teams to deliver intensive, facility-based therapy aimed at restoring patient functional ability and independence.
What sector is Encompass Health (EHC) in?
Encompass Health (EHC) is classified in the Health Care sector. Its industry is inpatient rehabilitation services. It trades on NYSE.
Does EHC pay a dividend?
Yes — Encompass Health (EHC) pays a dividend, with an indicated yield of about 0.68% and 3-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Encompass Health's (EHC) competitors?
Notable peers of Encompass Health (EHC) include Kindred Healthcare, Select Medical, HCA Healthcare, Community Health Systems and Universal Health Services. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in EHC?
Yes — we hold 4 matched STOCK Act disclosures for EHC from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Encompass Health (EHC) overbought or oversold right now?
Encompass Health (EHC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 46, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EHC come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.